What Are New Treatments for Frontotemporal Dementia?

As of 2026, there is no FDA-approved disease-modifying treatment that can stop or reverse frontotemporal dementia (FTD) ^[1][2]. Current medical care focuses on symptom management. Doctors may prescribe medications “off-label” to help with behavioral or mood changes, while speech, occupational, and physical therapies are used to maintain daily function and quality of life ^[2]. However, clinical research is an active area of investigation, particularly for patients with inherited (familial) forms of FTD ^[3].

Precision Medicine for Genetic FTD

While most cases of FTD are sporadic (occurring without a known family history), about a third are inherited. For these genetic cases, researchers are testing “precision medicine”—investigational therapies designed to address specific genetic variants like GRN (progranulin) and C9orf72 ^[4]. It is important to note that these experimental treatments are only being tested in patients who have these specific genetic variants.

GRN (Progranulin) Targeted Trials

A variant in the GRN gene causes a shortage of progranulin, a protein essential for brain health. Several early-phase clinical trials are testing different ways to replace or boost this protein ^[3]:

• Gene Therapies: Experimental treatments, such as PR006 (being studied in a Phase 1/2 trial), use a modified virus to deliver functional copies of the GRN gene into the body ^[5]. Other gene therapy programs, like PROCLAIM and ASPIRE-FTD, are also in development ^[6].
• Antibodies and Small Molecules: Latozinemab, an investigational monoclonal antibody, recently completed a Phase 1 safety study ^[7]. Small molecule drugs, such as those in the upliFT-D program, are also being evaluated ^[6].

While some of these early studies have successfully increased progranulin levels in patients’ blood or cerebrospinal fluid, this is only a “biomarker” finding ^[6][7]. It does not yet prove that the drugs can slow clinical decline, improve daily function, or are safe long-term.

C9orf72 Preclinical and Clinical Research

The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of familial FTD ^[4]. Progress here has been more challenging:

• Discontinued Trials: An early clinical trial for an antisense oligonucleotide (ASO) drug called BIIB078 was discontinued. While the drug successfully targeted the biological mechanism, it unfortunately did not improve clinical symptoms for patients ^[8][9].
• Preclinical Research: Researchers are using the lessons from BIIB078 to develop a new generation of treatments. Approaches like next-generation ASOs (synthetic molecules that alter specific RNA) and CRISPR gene-editing are actively being studied ^[10][11]. However, these are strictly in the laboratory (preclinical) phase and are not yet available in human trials ^[12].

Overview of Selected Targeted Therapies (As of 2026)

Note: Trial statuses change frequently. Early-phase trials primarily assess safety and dosing, not clinical benefit. Always consult your neurologist for up-to-date trial information.

Observational Studies and the FTD Disorders Registry

Because FTD is a rare and complex disease, researchers rely heavily on observational studies (such as ALLFTD and GENFI) and the FTD Disorders Registry to learn how the disease progresses ^[13][14].

• What the Registry Is: The FTD Disorders Registry is a voluntary database. Enrolling means you agree to share your contact information and basic health details. It may notify you of active trials you might qualify for, but it does not guarantee a trial match, enrollment, or personal medical benefit.
• Tracking Biomarkers: Observational studies often involve regular clinical visits, brain scans, and blood draws. Researchers use these visits to track markers like neurofilament light (NfL), a protein that indicates general nerve injury ^[15]. While NfL is not specific to FTD and cannot diagnose the disease alone, tracking it alongside memory and behavioral tests helps researchers measure disease progression over time ^[16].
• Future Prevention: By studying individuals who carry genetic variants but do not yet have symptoms, researchers hope to design future trials aimed at delaying or preventing the onset of symptoms ^[13].

Considering Genetic Testing and Trial Participation

If you have a family history of FTD, you may be considering genetic testing to see if you qualify for a trial.

• Genetic Counseling: Predictive genetic testing is deeply personal and voluntary. A genetic counselor can help you understand the emotional impact, privacy concerns, and implications for your blood relatives before you make a decision. A negative result does not necessarily rule out all inherited forms of FTD.
• What Trials Involve: Participating in a clinical trial is a significant commitment. Before joining, ask the study team about what is required. Trials may involve traveling to specialized centers, receiving a placebo (an inactive substance) instead of the drug, undergoing invasive procedures like lumbar punctures (spinal taps) or repeated MRIs, and stopping other medications. Participating in research is completely voluntary, and you can withdraw at any time.